We are thrilled to have had the opportunity to attend the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. Your interest in our research progress and the insightful discussions we had about your projects and objectives truly made our experience at AACR memorable. These exchanges are invaluable in advancing our collective efforts in cancer research.
We presented 20 posters including 9 antibody-based drug assets, 10 genetically engineered mouse models and 1 preclinical pharmacology study. Below, you will find all of the poster presentations from the conference available for download!
Modality |
Abstract Number |
Poster Title |
mAb |
LB130 |
|
TCRm |
6717 |
Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies |
bsAb |
2724 |
|
bsADC |
2620 |
|
2618 |
BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models |
|
2619 |
||
2617 |
||
LB127 |
A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model |
|
2616 |
Want to discuss parnership opportunities for our drug assets, fully human antibody discovery RenMice® platforms, mouse models, or preclinical pharmacology services? Contact us today!